GlassScriptPhysician profile
Lauren D Midthun
NPI 1629365176
$4,397.30
in general payments reported to CMS, 2019-2025
43 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $242 · 2021: $354 · 2022: $135 · 2023: $1,587 · 2024: $154 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $505.88 | 2023 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $306.30 | 2019-2025 | Pomalyst, Opdivo, Opdualag |
| Amgen INC. | $297.74 | 2020-2023 | Kyprolis, Blincyto |
| Bayer Healthcare Pharmaceuticals INC. | $283.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $259.44 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Lilly USA, LLC | $254.97 | 2019-2023 | Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $231.37 | 2022-2025 | Imfinzi, Calquence, Enhertu |
| Alexion Pharmaceuticals, INC. | $188.86 | 2020-2025 | Ultomiris |
| Genentech USA, INC. | $168.13 | 2020-2025 | Polivy, Rozlytrek, Tecentriq |
| Celgene Corporation | $134.40 | 2019-2023 | Reblozyl |
| Eisai INC. | $124.19 | 2021-2023 | |
| Blueprint Medicines Corporation | $106.22 | 2023 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $105.40 | 2020-2025 | Iclusig, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $104.01 | 2023-2025 | |
| Pfizer INC. | $100.89 | 2019-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $94.79 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $83.06 | 2023-2025 | Lynozyfic, Libtayo |
| Boston Scientific Corporation | $77.67 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Y90 Glass Microspheres 10 Gbq |
| Cti Biopharma Corp. | $69.85 | 2023 | Vonjo |
| Stemline Therapeutics INC. | $66.96 | 2024-2025 | Orserdu, Elzonris |
| Novocure INC. | $58.55 | 2023 | Optune |
| Beone Medicines USA, INC. | $55.50 | 2025 | Tevimbra |
| Incyte Corporation | $55.18 | 2023-2025 | Monjuvi, Zynyz, Jakafi |
| Genzyme Corporation | $54.91 | 2023-2025 | |
| Array Biopharma INC | $52.24 | 2025 | Lorbrena, Braftovi, Mektovi |
| Janssen Biotech, INC. | $50.18 | 2023-2025 | Darzalex, Talvey, Erleada |
| Daiichi Sankyo INC. | $47.64 | 2025 | Enhertu |
| Merck Sharp & Dohme LLC | $46.07 | 2023 | Lynparza, Keytruda, Welireg |
| Puma Biotechnology, INC. | $42.62 | 2019-2023 | |
| Caris Mpi, INC. | $34.13 | 2025 | Mi Cancer Seek |
| Seagen INC. | $33.25 | 2019-2021 | |
| Servier Pharmaceuticals LLC | $32.13 | 2025 | |
| Taiho Oncology, INC. | $30.75 | 2025 | |
| Karyopharm Therapeutics INC. | $27.53 | 2025 | Xpovio |
| Emd Serono, INC. | $27.14 | 2025 | |
| Sobi, INC | $27.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.82 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $25.20 | 2023 | Imbruvica |
| Helsinn Therapeutics (U.S.), INC. | $23.95 | 2025 | Akynzeo |
| Agios Pharmaceuticals, INC. | $23.64 | 2025 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $23.26 | 2025 | Clonoseq |
| Sumitomo Pharma America, INC. | $21.65 | 2025 | Orgovyx |
| Morphosys, US INC. | $13.92 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Midthun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.